argenx SE (ARGX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• ARGX Q2 2026: VivGuard Drives 60% Revenue Surge as Seronegative GMG Approval Expands Market
  July 24, 2026
• ARGX Q1 2026: $400M Cash Build and 90% Gross Margin Underscore Pipeline-Driven Immunology Expansion
  May 07, 2026
• ARGX Q4 2025: VivGuard Drives 90% Growth as Ocular MG Approval Targets 7,000-Patient Expansion
  February 26, 2026
• ARGX Q3 2025: Pre-Filled Syringe Drives 20% U.S. Growth, Expands Neurology Leadership
  October 30, 2025
• ARGX Q2 2025: Pre-Filled Syringe Drives 19% Sequential Growth, Expanding Patient Reach
  July 31, 2025
• ARGX Q1 2025: Pre-Filled Syringe Drives 50% New Patient Uptake, Expanding Market Reach
  July 06, 2025
• ARGX Q3 2024: CIDP Launch Adds 300 Patients, Validating Switch Market Strategy
  October 31, 2024
• ARGX Q2 2024: VivGuard Drives 20% QoQ Sales Jump, CIDP Launch Sets Stage for Multi-Indication Growth
  July 25, 2024
• ARGX Q1 2024: Vivgard Patient Base Surpasses 10,000 as Subcutaneous Uptake Accelerates 34%
  May 09, 2024
• ARGX Q4 2023: VivGuard Drives $1.2B U.S. Revenue as Pipeline Readies for Five New Indications
  February 29, 2024

Browse all companies